US Will Work With Foodmakers to Stop the Use of Synthetic Dyes
Food and Drug Administration Commissioner Marty Makary said Tuesday the agency would work with the industry to eliminate six synthetic dyes by the end of 2026, including Red 40, Yellow 5 and Blue 1. The FDA will also ask the industry to eliminate Red 3 before 2027, the timeline set by the Joe Biden administration.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
27 minutes ago
- CBS News
Florida officials warn about risks of drinking raw milk after 21 people sickened
The Florida Department of Health is warning about the risks of drinking raw, unpasteurized milk after 21 people, including six children under the age of 10, were sickened by E. coli and campylobacter bacteria linked to raw milk from the same farm. Seven people have been hospitalized, and two have developed severe complications. "Sanitation practices in this farm are of particular concern due to the number of cases," the department said in a news release. Officials did not identify the farm, but indicated its products were available in Northeast and Central Florida. Although it is illegal to sell raw milk for human consumption in Florida, it can be sold in the state if it's labeled as a pet food. Raw milk has been promoted by online wellness influencers and raw food advocates, boosting sales in recent years, but public health officials say it can be risky. The Food and Drug Administration and the Centers for Disease Control and Prevention say raw milk can carry life-threatening bacteria, such as E. coli, campylobacter, listeria or salmonella. These can cause symptoms including diarrhea, vomiting and stomach cramps. Severe cases can result in a condition called hemolytic uremic syndrome, or HUS, which can lead to kidney failure. Since 1987, 143 outbreaks have been linked to raw milk or raw milk products, some involving miscarriages, stillbirths, kidney failure and even deaths, according to the FDA. Pasteurization — a process of heating the milk — kills these bacteria. Pasteurization is required by federal law for any milk sold across state lines. Some individual states also restrict or ban the sale of raw milk, but others allow it. In an interview with CBS News Miami earlier this year, Mark McAfee, founder of one of the world's largest raw milk producers and head of an advocacy group called the Raw Milk Institute, claimed raw milk offers health benefits such as bioactives that boost the immune system. McAfee sells his raw milk legally in California, where no state law prohibits its sale. But the CDC says such claims are unfounded. "Pasteurized milk offers the same nutritional benefits without the risks of raw milk consumption," the agency says. The Florida Department of Health noted in its statement that "many people consume raw milk safely." But it also advised, "Floridians should be aware of potential risks associated with consumption, which may vary depending on the source of producer's handling of raw milk and milking procedures are vital in prevention of contamination."
Bloomberg
an hour ago
- Bloomberg
FDA Chief Says He Wants Gene Therapy Head Prasad to Return
By and Skylar Woodhouse Save US Food and Drug Administration Commissioner Marty Makary said he's trying to persuade Vinay Prasad, the agency's former head of gene therapy and vaccines, to return to the FDA after his abrupt departure last week. Makary told reporters Monday that media reports suggesting that Prasad was fired after intervention from the White House are 'simply untrue.' He 'didn't want to be a distraction,' Makary said.
Miami Herald
an hour ago
- Miami Herald
enVVeno Medical Participates in a New Virtual Investor "What This Means" Segment to Discuss How President Trump's Recent CVI Diagnosis May Impact the Company
- enVVeno is developing the VenoValve as a potential treatment option for the approximately 2.5 million patients in the U.S. suffering from severe deep Chronic Venous Insufficiency - FDA decision expected in 2H'2025 - Access the "What This Means" segment here IRVINE, CA / ACCESS Newswire / August 4, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno Medical" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that it participated in a Virtual Investor "What This Means" segment entitled, "enVVeno Medical - Making Veins Work Again - How President Trump's CVI Diagnosis is Raising Awareness." Rob Berman, CEO and Dr. Marc Glickman, CMO of enVVeno Medical discussed the progressive nature of chronic veinous insufficiency and whether President Trump may one day be a candidate for the VenoValve® following U.S. Food and Drug Administration (FDA) approval. The Company estimates that there are approximately 2.5 million patients in the U.S. that could be candidates for the VenoValve. The Company has submitted a pre-market authorization (PMA) application for the VenoValve to the FDA, with a decision anticipated in the second half of 2025. The "What This Means" segment can be accessed here. About CVI Severe deep venous CVI is a serious and debilitating disease that is most often caused by blood clots (deep vein thromboses or DVTs) in the deep veins of the leg. When valves inside of the veins of the leg fail, blood flows in the wrong direction and pools in the lower leg, causing pressure within the veins of the leg to increase (venous hypertension). Symptoms of CVI include leg swelling, pain, edema, and in the most severe cases, recurrent open sores known as venous ulcers. The disease can severely impact everyday functions such as sleeping, bathing, dressing, and walking, and is known to result in high rates of depression and anxiety. There are currently no effective treatments that repair deep venous valve dysfunction, the #1 cause of severe CVI-a disease estimated to cost the U.S. healthcare system in excess of $26 billion each year. About enVVeno Medical Corporation enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease. The Company's lead product, the VenoValve®, is a first-in-class surgical replacement venous valve being developed for the treatment of deep venous Chronic Venous Insufficiency (CVI). The Company is also developing a non-surgical, transcatheter based replacement venous valve for the treatment of deep venous CVI called enVVe®. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the leg, and back to the heart and lungs. The VenoValve is currently being evaluated in the VenoValve U.S. pivotal study and the Company is currently performing the final testing necessary to seek approval for the pivotal trial for enVVe. INVESTOR CONTACT: Jenene Thomas, JTC Team, LLCNVNO@ 824-0775 MEDIA CONTACT:Glenn Silver, FINN 818-8198 SOURCE: enVVeno Medical Corporation
